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A better understanding of the inﬂammatory mechanisms of rheumatoid arthritis and the
development of biological therapy revolutionized its treatment, enabling an interference in
the  synovitis – structural damage – functional disability cycle. Interleukin 33 was recently
described as a new member of the interleukin-1 family, whose common feature is its pro-
inﬂammatory activity. Its involvement in the pathogenesis of a variety of diseases, including
autoimmune diseases, raises the interest in the possible relationship with rheumatoid
arthritis. Its action has been evaluated in experimental models of arthritis as well as in
serum, synovial ﬂuid and membrane of patients with rheumatoid arthritis. It has been
shown that the administration of interleukin-33 exacerbates collagen-induced arthritis in
experimental models, and a positive correlation between cytokine concentrations in serum
and  synovial ﬂuid of patients with rheumatoid arthritis and disease activity was found. This
review discusses evidence for the role of interleukin-33 with a focus on rheumatoid arthritis.
©  2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Ac¸ão  da  IL33  na  artrite  reumatoide:  contribuic¸ão  para  a  ﬁsiopatalogia
alavras-chave:
nterleucina 33
rtrite reumatoide
r  e  s  u  m  o
A melhor compreensão dos mecanismos inﬂamatórios da artrite reumatoide e o desen-
volvimento da terapia biológica revolucionaram o tratamento da doenc¸a, permitindo uma
interferência no ciclo sinovite–dano estrutural–incapacidade funcional. A interleucina 33 foi
isiopatologia recentemente descrita como um novo membro da família da interleucina 1, cuja caracterís-
ade pró-inﬂamatória. Por estar envolvida na patogênese de uma grandetica  comum é a atividvariedade de doenc¸as, incluindo doenc¸as autoimunes, a interleucina 33 comec¸a a ser estu-
dada  na doenc¸a reumatoide. Ela tem sido avaliada em modelos experimentais de artrite, no
soro, no líquido e membrana sinoviais de pacientes com artrite reumatoide. Demonstrou-se
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que a administrac¸ão da interleucina 33 exacerba a artrite induzida por colágeno em modelos
experimentais, e concentrac¸ões dessa citocina no soro e no líquido sinovial de pacientes
com  artrite reumatoide correlacionaram-se positivamente com a atividade da doenc¸a. Esse
manuscrito apresenta a interleucina 33 e discute as evidências do seu papel em diferentes
doenc¸as, com ênfase na artrite reumatoide.
©  2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CCIntroduction
Rheumatoid arthritis (RA) comprises a symmetric polyarthri-
tis affecting diarthrodial joints and periarticular structures,
besides presenting several systemic manifestations. RA
affects about 1% of the world population and is commonly
associated with functional disability and reduced quality of
life.1,2
The primary inﬂammatory site of RA is the synovial mem-
brane (SM) which shows cell hyperplasia and an inﬂammatory
process, settling a case of synovitis. When this disease pro-
gresses without treatment, or even in the most refractory
cases, there is progressive joint destruction with cartilage and
bone loss.3
The inner face of SM is in contact with the intra-articular
cavity and, usually, this is a delicate two- or three-cell layer
membrane. In RA, a large number of immune cells invade
this structure, leading to cell proliferation, neovascularization
and the formation of germinal lymphoid follicles. The mech-
anisms involved in the recruitment of inﬂammatory cells
into the synovial membrane have been extensively studied.4
Changes in the function of T and B cells, and an abnormal
production of cytokines and antibodies have been recognized
as processes present in RA.5–8 Many  cytokines responsible for
regulating cell communication are expressed in the synovial
membrane, being directly involved in immune processes in
cases of RA.
The study of the role of cytokines has led to the devel-
opment of new therapeutic agents for the treatment of RA,
including tumor necrosis factor alpha (TNF-alpha) and inter-
leukin receptor (IL) 6 blockers. Recent observations in humans
and experimental studies have shown the potential role of IL-
33 and its receptor ST2 as mediators in the pathogenesis of
RA.9,10 IL-33 has been identiﬁed as a new IL-1 family member,
which also includes IL-1alpha, IL-1beta, IL-18 and the antag-
onist of the IL-1 receptor (IL-1Ra).11 This paper presents the
actions of IL-33 and discusses its role in RA.
Interleukin  33
IL-33 was recently described as a new member of the IL-1
family, whose common characteristic is the pro-inﬂammatory
activity.11–13 IL-33 plays an important immune role associated
with Th2 response, signiﬁcantly stimulating the secretion of
IL-5 and IL-13 by Th2 polarized cells.
The IL-33 gene is located on chromosome 9 (9p24.1).
Messenger RNA (mRNA) of IL-33 is expressed in multiple cell
types in different organs, both in humans and in mice. TheBY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
IL-33 protein is mainly expressed in epithelial and endothelial
cells, particularly in high endothelial venules.14
Similar to IL-1beta and IL-18, IL-33 is produced intracellu-
larly as pro-IL-33 and, after undergoing cleavage, is secreted
extracellularly as the mature form of IL-33.14 Its bioactive
form is released as a result of cell necrosis and serves as an
inﬂammatory trigger through autocrine and paracrine action.
Caspase-1, also known as IL-1 beta converting enzyme, is
responsible by the cleavage of pro-forms of some cytokines
of the IL-1 family, such as pro-IL-1beta and interferon gamma
(IFN-gamma) inducing IL-18. It has also been demonstrated
in vitro that IL-33 is cleaved by caspase-1, although the in vivo
relevance of this enzyme is still under dispute.15 Although IL-
33 is structurally related to IL-1beta and IL-18, that activate
Th1/Th17 cells, their biological functions result mainly in the
production of IL-5 and IL-13.11
The IL-33 receptor is a complex formed by  ST2 protein
and by accessory protein for IL-1 receptor (IL-1RAcP), both
expressed in most cells, mainly mast cells and in activated Th2
cells. Three isoforms of ST2 in humans are produced by differ-
ential processing of a single copy: membrane-anchored form
(ST2), soluble form (sST2), and a form expressed mainly in gas-
trointestinal organs (ST2V). The sST2 form works as a decoy
receptor of IL-33, by blocking its binding to the transmembrane
receptor.11
The functions or effects of IL-33 are present in various cell
types, and prompted studies on the participation of this inter-
leukin and its receptor in different clinical conditions such as
asthma, sepsis, atherosclerosis and rheumatoid arthritis.
IL-33  in  in  vitro  and  in  experimental  studies
Several experimental studies describe the cellular actions of
IL-33. IL-33 secretion has been described in a monocyte lineage
(THP-1 cells) in response to different stimuli: infection (Listeria
monocytogenes and Salmonella typhimurium), lipopolysaccharide
(LPS) with aluminum adjuvant, and LPS alone.16,17
Basophils activated by immunoglobulin E (IgE) produce IL-
33 and release histamine and, additionally, basophil migration
also appears to be regulated by IL-33. These ﬁndings aid in the
understanding of independent immune responses of antigens
present in tissues that express the mRNA  of IL-33, for instance,
smooth muscle cells in bronchial tissue and epithelial cells of
the airways.18,19
In eosinophils, IL-33 regulates the activation, degranula-
tion and increased adherence and survival.16,20 In mice, after
systemic administration, IL-33 is a powerful inducer of innate
response type 2; this was demonstrated by the development of
splenomegaly, eosinophilia and severe changes in the bowel
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nd lungs by the animals – effects accompanied by an increase
f immunoglobulins E and A and of cytokines of the Th2
esponse.11 An experimental study showed that IL-33 admin-
stration to mice was able to induce anaphylaxis.21
In mice sensitized with IL-33, there was an increase of
FN-gamma; this ﬁnding provided support for the conclusion
hat IL-33 may act as a costimulatory factor in cellular innate
mmune responses.22
Mast cells are very responsive to IL-33, which results
n increased production of IL-6, IL-13, IL-1beta, TNF,
rostaglandin D2 and MCP-1.23–26 In addition, IL-33 promotes
urvival, adhesion and cytokine production in human mast
ells and also in mast cell progenitors.24,27
Cardiomyocytes can also be activated by IL-33.15,16,28 IL-33
roduced by cardiac ﬁbroblasts antagonizes the hypertrophic
ction induced by angiotensin II and phenylephrine on car-
iomyocytes. Thus, it is believed that IL-33 might potentially
xert a beneﬁcial therapeutic effect on the regulation of
yocardial response to overload.28
Regarding asthma, experimental models suggest that the
T2 receptor is involved in airway inﬂammation mediated
ntigen.16,29 In the experimental asthma induced by oval-
umin, an IL-33 injection by intraperitoneal route resulted in
osinophilia and accumulation of macrophages in the lungs
f animals. In contrast, ST2 receptor-deﬁcient mice developed
n attenuated inﬂammation in its airways and low levels of
L-5 and eosinophils in serum.13,30
Another prominent action of IL-33 seems to occur in
elation to the defense against infection. Toll-like receptors
TLRs) participate in the inﬂammatory initiation mechanism
n infectious processes, by recognizing Pathogen-associated
olecular patterns (PAMPs) and endogenous ligands released
y damage-associated molecular patterns (DAMPs). The bind-
ng of IL-33 to ST2 receptor can downregulate the activation
f TLRs, by competing for the use of MyD88 signaling
omponent.31 Recently, Alves-Filho et al. found that IL-33 has
 protective action in experimental cases of sepsis in mice,
y showing that the inﬂammatory process was attenuated
y treatment with recombinant IL-33. Since the activation of
LRs in neutrophils leads to suppression of the regulation of
nterleukin-8 beta receptor expression (CXCR2), critical for the
ecruitment of cells to the site of infection, the concurrent
ction of IL-33 by MyD88 protein decreases activation of TLRs
nd, in consequence, allows a greater expression of CXCR2,
ot inhibiting the inﬂux of neutrophils to the infected site and
roviding an acceleration of bacterial clearance.32
L-33  in  human  studies
s well as in experimental models, the participation of IL-33
nd of its receptor ST2 has been investigated in several clinical
onditions.
Serum levels of sST2 are increased in patients with acute
sthma exacerbations, and patients with chronic asthma have
igh pulmonary concentrations of IL-33.17 Bearing in mind
hat ST2 is preferentially expressed on Th2 cells and mast
ells, this provides reasoning for explaining the association
etween high levels of IL-33 and asthma.30
In infectious processes, IL-33 promotes greater expression
f surface receptor ligands of type CXCR2 cytokines, which are 6;5 6(5):451–457 453
associated with migration of neutrophils to the site of infec-
tion and with bacterial clearance. It was shown that patients
who have not recovered from a septic event expressed signiﬁ-
cantly lower concentrations of CXCR2 than those patients who
have been healed. In addition, non-survivor septic individuals
exhibited higher serum concentrations of sST2 as compared
to those who survived. Given that sST2 is a decoy receptor for
IL-33, these ﬁndings suggest that IL-33 is associated with a
favorable outcome in a scenario of clinical sepsis.13,32
Recent studies suggest a protective role for IL-33/ST2 com-
plex in cases of atherosclerosis and obesity, and also in
cardiac remodeling in humans. IL-33 and its receptor ST2 seem
to play a positive role in the progression of atherogenesis,
and also protect the heart against the action of deleteri-
ous forces responsible for dilatation, muscle hypertrophy
and ﬁbrosis.33 In humans, this cytokine reduces apoptosis of
cardiomyocytes, improving left ventricular function through
the suppression of caspase-3 and increased expression of
inhibitor of apoptosis proteins.34 It has been demonstrated
that elevated serum levels of sST2 measured immediately
after an acute myocardial infarction exhibited a direct cor-
relation with serum creatine kinase levels and an inverse
correlation with the ejection fraction of the left ventricle. In
these patients, the levels of sST2 were higher in those patients
who died or who have developed congestive heart failure.34
Complementarily, a clinical trial that evaluated patients in
the ﬁrst 12 h after an episode of acute coronary syndrome
with ST-segment elevation showed that increased levels of
sST2 at the initial assessment were predictors of heart failure.
In addition, the combined evaluation of the ST2 and B-type
natriuretic peptide (NT-proBNP) improved the prediction of
cardiovascular death in these patients.34
The binomial IL-33/ST2 has been investigated in several
rheumatic diseases. In patients with systemic lupus erythe-
matosus (SLE), serum sST2 was higher than in healthy controls
and, in addition, showed a positive correlation with disease
activity (by SLEDAI index and serum anti-DNA antibody). SLE
patients showed an inverse correlation between sST2 and
serum levels of complement C3, suggesting that sST2 is a
marker of disease activity. Serum IL-33 was comparable to
healthy controls, and showed no correlation with levels of
sST2, lupus activity, or involvement of a speciﬁc organ.35 In
spondyloarthritis, serum IL-33 levels were signiﬁcantly higher
in patients versus controls. Serum levels of ST2 differ between
patients with ankylosing spondylitis and controls, but with no
correlation with disease activity. Contrary to what occurs in
patients with SLE, in cases of spondyloarthritis the ST2 recep-
tor appears to act as a disease activity marker.36
Terras et al. found elevated serum levels of IL-33 in
patients with systemic sclerosis versus healthy controls. In
these patients, IL-33 was associated with early disease and
microvascular involvement. These authors believe that, in the
future, IL-33 will help to predict the onset of recurrent digital
ulcers.37
In young people with juvenile idiopathic arthritis (JIA),
the action of IL-33 and its receptor was evaluated. In 24
patients with the systemic type, ﬁve patients with polyartic-
ular JIA associated with rheumatoid factor, four patients with
macrophage activation syndrome and 20 healthy controls,
serum levels of IL-33 and sST2 were measured. In patients
 o l . 2 0 1 6;5 6(5):451–457
Table 1 – Participation of interleukin 33 and its receptor
ST2 in infectious, metabolic and inﬂammatory diseases.
Disease Role of IL-33 and ST2 receptor
Alzheimer’s disease Reduced brain expression of IL-33
gene
Inﬂammatory bowel
disease
Increased IL-33 regulation in
colonic cells
Autoimmune encephalitis Increased expression of ST2 in the
spinal cord of mice with
autoimmune encephalitis
Hepatitis B Severe  encephalitis induced by
IL-33 in experimental model
Hepatitis C Exacerbation of encephalitis in
ST2-deﬁcient mice
Chronic renal failure IL-33 and sST2 serum levels are
elevated compared to healthy
controls
Leishmania major Reduced serum levels of IL-33 with
treatment
Acute pancreatitis IL-33 and sST2 serum levels
increased compared to controls
and to those with spontaneous
resolution of hepatitis C
Pseudomonas aeruginosa Positive correlation between IL-33
and serum transaminases
Toxoplasma gondii Elevated serum concentration of
sST2 compared to healthy controls
Trichuris muris Relationship between sST2 and
disease severity
Human immunodeﬁciency
virus
Increased resistance conferred by
anti-ST2 in an experimental model
Inﬂuenzae virus Early elevation of serum sST2
Respiratory syncytial virus Correlation between sST2 and454  r e v b r a s r e u m a t
with systemic JIA, serum levels of IL-33 were detected in
only four of 24 patients analyzed, and this cytokine did not
correlate with disease activity or to sST2 levels. Moreover,
serum levels of IL-33 were signiﬁcantly increased in patients
with rheumatoid factor-positive polyarticular JIA, compared
to healthy controls. Serum levels of sST2 in patients with
macrophage activation syndrome and in patients with active
systemic JIA were signiﬁcantly higher versus patients with
polyarticular JIA associated with rheumatoid factor and versus
healthy controls. In cases of systemic JIA, the sST2 levels were
normalized in the remission stage. In cases of macrophage
activation syndrome, serum levels of sST2 rose rapidly, with
a gradual decrease after clinical resolution. The mechanisms
proposed to explain the discrepancy between IL-33 and SST2
levels in systemic JIA are: formation of immune complexes of
IL-33 with sST2, or as a result of the decoy receptor function
assigned to sST2, as already discussed. The authors conclude
that despite the small number of patients studied, the ST2
receptor may be an important mediator in cases of systemic
JIA, providing a promising marker of disease activity, or even
a new therapeutic target.38
Also in the group of rheumatic diseases, IL-33 and its
receptor have been associated with systemic vasculitis. In
patients with Behcet’s disease, IL-33 serum levels were higher
in patients with active disease compared to healthy controls
or patients with inactive disease.39 Ciccia et al. identiﬁed sig-
niﬁcantly higher levels of ST2 and IL-33 in inﬂamed arteries
of patients with giant cell arteritis, and the major sites of
expression of IL-33 were found in the neovascularization. In
addition, the arteries of patients treated with glucocorticoids
showed lower expression of this cytokine. It was noteworthy
that increased expression of IL-33 was not related to a con-
comitant increase in cytokines of Th2 group, suggesting that
IL-33 could act early in the disease, promoting arterial inﬂam-
mation and angiogenesis, as well as modulating the innate
immune response by a regulation of macrophage action.40
Evaluating patients with Henoch-Schönlein purpura, Chen
et al. demonstrated that serum levels of IL-33, but not of sST2,
were higher in these patients during the acute phase, but
returning to normal values in the convalescent phase. In this
analysis, the serum levels of this cytokine were correlated with
the severity of the disease and serum concentrations IgA-type
anti-endothelial antibody and IgA anticardiolipin antibody.41
Furthermore, the involvement of IL-33 has been described
in several other diseases of different etiopathogenesis as
shown in Table 1.13,42–49
Interleukin-33  and  rheumatoid  arthritis
The role of IL-33/ST2 complex has been much discussed in RA,
mainly from the ﬁndings that IL-33 expression is increased in
synovial membrane.50
Several studies using experimental models of arthritis have
evaluated the participation of IL-33 in pictures of joint inﬂam-
mation. The ﬁrst study to evaluate the association of IL-33
with joint inﬂammation in animal models of arthritis was
Damo et al., who  described the role of IL-33 in experimen-
tal collagen induced arthritis (CIA) in mice. These authors
demonstrated that IL-33 increased the response in a CIA
model by activating mast cells, which express high densityseverity parameters
of ST2. Proposed mechanisms for joint inﬂammation induc-
tion by IL-33 were activation of mast cells, and therefore, the
production of inﬂammatory cytokines; increased secretion of
IL-6 and IL-1beta by activated mast cells; or CD4+ T cells stim-
ulation that would lead to production of IL-5 and IL-13. This
latter mechanism would increase the activation of B cells and
immunoglobulin production, worsening the joint inﬂamma-
tion process and stimulating mast cell degranulation and the
formation of immune complexes with collagen. These authors
also demonstrated that, in this experimental model, mast cells
are important, albeit not essential for the development of
arthritis.23
In contrast, Lee et al. showed that mast cell-deﬁcient mice
were completely resistant to the induction of arthritis.51 The
reasons for this difference are not clear, but may be due to
the fact that the animals used by Lee et al. were also deﬁcient
in neutrophils, unlike the experiments conducted by Damo
et al. This could explain the different results, especially con-
sidering the critical role of neutrophils in the pathogenesis of
CIA.23,51
Strengthening the role of neutrophils in this process, Verri
et al. demonstrated that IL-33 is a potent chemical attractor
for neutrophils in an experimental model of arthritis induced
by methylated bovine serum albumin. IL-33 was produced
mainly by FS and macrophages through the adaptive immune
response. Although the exact nature of the induction of IL-33
synthesis in these cells is still unknown, it is likely that there is
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nvolvement of the effect of inﬂammatory cytokines produced
y T cells and macrophages after challenging with a spe-
iﬁc antigen. In the presence of IL-33, occurs a recruitment of
eutrophils to the joint site via at least two mechanisms: stim-
lating the production of TNF and IL-1beta by macrophages
nd synoviocytes, in addition to the surface receptor ligands
f cytokines of types CXCL1 and CCL3, which, in turn, would
llow the recruitment of neutrophils to the joint space; or IL-
3 could directly activate neutrophils, recruiting these cells to
he site of inﬂammation.52
Paradoxically, in a recent experiment in mice with CIA
eceiving IL-33 intraperitoneally, these authors showed the
ccurrence of inhibition of the development of arthritis after
dministration of this cytokine. This effect was associated
ith an improved immune response type 2, including the
xpansion of eosinophils, innate lymphoid cells type 2 and
ells and cytokines from Th2 group. Since IL-33 acts directly on
reg cells via ST2, it was proposed that the treatment of these
nimals with IL-33 would enhance the suppressive capacity of
uch cells. Thus, these authors believe that IL-33 might exert
nti-inﬂammatory properties in CIA.53
Concurrently with experimental studies, the demonstra-
ion of the presence of IL-33 and ST2 in the synovium of
atients with RA has aroused great interest for the role of this
omplex in the pathogenesis of the disease.10
Palmer et al. detected an expression of IL-33 in human
ynovial tissue samples, in SF cultures of patients with RA,
nd in FS cultures of mice with arthritis. IL-33 was also found
n endothelial cells of normal and inﬂamed synovial tissue.
uman SF of RA patients constitutively expressed low lev-
ls of this cytokine, and the expression of mRNA  and IL-33
rotein increased after treatment with IL-1beta or TNF-alpha.
hese authors concluded that IL-33 is locally produced in
nﬂamed tissues and that its neutralization may exert ther-
peutic effects in RA.54
The precursor of IL-33 was detected in the supernatant of
S cultures stimulated with TNF and IL-1beta. These results
ndicate that IL-33 is locally produced in inﬂamed joints and
hat, furthermore, the neutralization of IL-33 action has a ther-
peutic effect in the course of arthritis. In the CIA animal
odel, administration of a blocking antibody of ST2 attenu-
ted the severity of arthritis and decreased joint destruction
ssociated with the decreased production of IFN-gamma, as
ell as a reduction in IL-17 production. In addition, the levels
f mRNA  of the receptor activator of nuclear factor kappa B
igand (RANKL) diminished with the use of anti-ST2. These
esults indicate that IL-33 is locally produced in inﬂamed
oints, and that the neutralization of IL-33 action has a thera-
eutic effect in the course of arthritis.22,54
In vivo, the expression of IL-33 is also induced in stimu-
ated FS, suggesting that this expression can be maintained in
n environment ﬁlled with cytokines, promoting the mainte-
ance of chronic inﬂammation.10
The ﬁrst study to identify high levels of IL-33 in serum
nd synovial ﬂuid of patients with RA was that of Matsuyama
t al., comparing these levels versus patients with infectious
iseases and healthy individuals. In RA patients, a positive
orrelation between serum levels of IL-33 to disease activity
sing the Disease Activity Score 28 (DAS28) was observed. The
umber of painful and swollen joints was highest in the group 6;5 6(5):451–457 455
positive for IL-33, while C-reactive protein (CRP), IL-1beta, IL-6
and TNF-alpha did not differ between groups.55
Hong et al. also found serum levels of IL-33 and sST2 signif-
icantly higher in patients with RA versus healthy controls.10
It is worth mentioning the fact that serum levels of IL-33,
sST2 and CRP were assessed before and after treatment with
disease-modifying anti-rheumatic drugs (DMARDs). Of the ten
patients, nine have received more  than one type of synthetic
DMARDs. Serum IL-33, sST2 and CRP decreased after treat-
ment with DMARDs in patients with RA; furthermore, the
authors found a positive correlation between the reduction of
IL-33 concentration and the level of CRP after treatment. No
relationship was found between sST2 values and CRP concen-
tration changes.
Xiangyang et al. analyzed IL-33 levels in serum from RA
patients and additionally investigated the pathophysiological
importance of this cytokine (reference). Serum levels of this
cytokine were higher in RA patients versus healthy controls,
and these authors also observed a positive and signiﬁcant cor-
relation between IL-33 levels, positivity for anti-citrullinated
protein antibodies and rheumatoid factor, and levels of matrix
metalloproteinase (MMP) 3. In that study its authors also noted
a strong correlation between serum levels of IL-33 and the
Sharp score (modiﬁed) in patients with RA. These data arouse
great interest in the use of IL-33 as a prognostic marker in
patients with RA, although this study did not ﬁnd any cor-
relation between IL-33 levels and other clinical parameters,
such as erythrocyte sedimentation rate, CRP and DAS28. In this
study it was also demonstrated that the serum level of IL-33
was signiﬁcantly increased in patients with interstitial lung
disease, as compared to patients without lung involvement,
suggesting that IL-33 would be associated with interstitial lung
disease of RA.56
Perspectives
RA is a chronic arthropathy associated with joint damage and
disability and functional decline.57 Along with a better under-
standing of the pathophysiology of RA, the incorporation of
genetic and molecular technologies has allowed the develop-
ment of therapeutic procedures and improved the prognosis
of patients.58 The identiﬁcation of the pro-inﬂammatory role
of IL33 demonstrated by its expression in the synovium of
patients with RA, indicates that this interleukin may be a ther-
apeutic target.23
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